Anebulo Pharmaceuticals, Inc. (NASDAQ:ANEB) Sees Large Decrease in Short Interest

Anebulo Pharmaceuticals, Inc. (NASDAQ:ANEB) was the target of a large decrease in short interest in November. As of November 15th, there was short interest totalling 6,500 shares, a decrease of 39.8% from the October 31st total of 10,800 shares. Currently, 0.1% of the company’s stock are short sold. Based on an average trading volume of 8,900 shares, the days-to-cover ratio is currently 0.7 days.

Anebulo Pharmaceuticals Price Performance

NASDAQ ANEB traded up $0.01 during trading hours on Friday, hitting $1.44. The company’s stock had a trading volume of 4,930 shares, compared to its average volume of 6,747. Anebulo Pharmaceuticals has a 12 month low of $1.25 and a 12 month high of $3.30. The company’s 50 day simple moving average is $1.82 and its two-hundred day simple moving average is $2.04.

Anebulo Pharmaceuticals (NASDAQ:ANEB) last released its quarterly earnings data on Wednesday, September 25th. The company reported ($0.05) earnings per share for the quarter, beating the consensus estimate of ($0.13) by $0.08. On average, sell-side analysts forecast that Anebulo Pharmaceuticals will post -0.52 EPS for the current year.

Wall Street Analyst Weigh In

Separately, Benchmark reissued a “speculative buy” rating and issued a $8.00 target price on shares of Anebulo Pharmaceuticals in a report on Tuesday, November 19th.

About Anebulo Pharmaceuticals

Anebulo Pharmaceuticals, Inc, a clinical-stage biotechnology company, engages in developing solutions for people suffering from acute cannabinoid intoxication (ACI) and substance addiction. The company's lead product candidate is ANEB-001, a small molecule cannabinoid receptor antagonist, which is in a Phase II clinical trial to address the unmet medical need for a specific antidote for ACI.